Brain uptake of multivalent and multi-specific DVD-Ig proteins after systemic administration

References

• Abbott NJ. Blood-brain barrier structure and function and the challenges for CNS drug delivery. J Inherited Metabolic Dis. 2013;36(3):437–49. doi:10.1007/s10545-013-9608-0.
   PubMed Web of Science ®Google Scholar
• Neuwelt E, Abbott NJ, Abrey L, Banks WA, Blakley B, Davis T, Engelhardt B, Grammas P, Nedergaard M, Nutt J, et al. Strategies to advance translational research into brain barriers. Lancet Neurol. 2008;7(1):84–96. doi:10.1016/S1474-4422(07)70326-5. PMID:18093565.
   PubMed Web of Science ®Google Scholar
• Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discovery. 2014;13(9):655–72. doi:10.1038/nrd4363. PMID:25103255.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Drug transport across the blood-brain barrier. J Cerebral Blood Flow Metab. 2012;32(11):1959–72. doi:10.1038/jcbfm.2012.126.
   PubMed Web of Science ®Google Scholar
• Abuqayyas L, Balthasar JP. Investigation of the role of FcgammaR and FcRn in mAb distribution to the brain. Mol Pharmaceutics. 2013;10(5):1505–13. doi:10.1021/mp300214k.
   PubMed Web of Science ®Google Scholar
• Watts RJ, Dennis MS. Bispecific antibodies for delivery into the brain. Curr Opin Chem Biol. 2013;17(3):393–9. doi:10.1016/j.cbpa.2013.03.023. PMID:23570979.
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu L. Modern methods for delivery of drugs across the blood-brain barrier. Adv Drug Delivery Rev. 2012;64(7):640–65. doi:10.1016/j.addr.2011.11.010.
   PubMed Web of Science ®Google Scholar
• Roy S. Strategic drug delivery targeted to the brain: A review. Der Pharmacia Sinica. 2012;3(1):76–92.
   Google Scholar
• Desai N. Challenges in development of nanoparticle-based therapeutics. AAPS J. 2012;14(2):282–95. doi:10.1208/s12248-012-9339-4. PMID:22407288.
   PubMed Web of Science ®Google Scholar
• Singh S. Nanomaterials as Non-viral siRNA delivery agents for cancer therapy. BioImpacts: BI. 2013;3(2):53–65. PMID:23878788.
   PubMedGoogle Scholar
• Patel M, Souto EB, Singh KK. Advances in brain drug targeting and delivery: limitations and challenges of solid lipid nanoparticles. Exp Opin Drug Delivery. 2013;10(7):889–905. doi:10.1517/17425247.2013.784742.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Drug targeting to the brain. Pharm Res. 2007;24(9):1733–44. doi:10.1007/s11095-007-9324-2. PMID:17554607.
   PubMed Web of Science ®Google Scholar
• Pardridge WM, Buciak JL, Friden PM. Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. J Pharmacol Exp Ther. 1991;259(1):66–70. PMID:1920136.
   PubMed Web of Science ®Google Scholar
• Pardridge WM, Kang YS, Buciak JL, Yang J. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharmaceutical Res. 1995;12(6):807–16. doi:10.1023/A:1016244500596.
   PubMed Web of Science ®Google Scholar
• Stanimirovic D, Kemmerich K, Haqqani AS, Farrington GK. Engineering and pharmacology of blood-brain barrier-permeable bispecific antibodies. Adv Pharmacol. 2014;71:301–35. doi:10.1016/bs.apha.2014.06.005. PMID:25307221.
   PubMedGoogle Scholar
• Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y, Atwal J, Elliott JM, Prabhu S, Watts RJ, et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med. 2011;3(84):84ra44. doi:10.1126/scitranslmed.3002230. PMID:21613623.
   PubMed Web of Science ®Google Scholar
• Yu YJ, Atwal JK, Zhang Y, Tong RK, Wildsmith KR, Tan C, Bien-Ly N, Hersom M, Maloney JA, Meilandt WJ, et al. Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates. Science Transl Med. 2014;6(261):261ra154. doi:10.1126/scitranslmed.3009835.
   PubMed Web of Science ®Google Scholar
• Hackel BJ, Bohrmann B, Collin L, Urich E, Sade H, Maier P, Rueger P, Stracke JO, Lau W, Tissot AC, et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron. 2014;81(1):49–60. doi:10.1016/j.neuron.2013.10.061. PMID:24411731.
   PubMed Web of Science ®Google Scholar
• Bien-Ly N, Yu YJ, Bumbaca D, Elstrott J, Boswell CA, Zhang Y, Luk W, Lu Y, Dennis MS, Weimer RM, et al. Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants. J Exp Med. 2014;211(2):233–44. doi:10.1084/jem.20131660. PMID:24470444.
   PubMed Web of Science ®Google Scholar
• Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, Bose S, McCarthy D, Zhu RR, Santora L, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol. 2007;25(11):1290–7. doi:10.1038/nbt1345. PMID:17934452.
   PubMed Web of Science ®Google Scholar
• Gu J, Ghayur T. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting. Methods Enzymol. 2012;502:25–41. doi:10.1016/B978-0-12-416039-2.00002-1. PMID:22208980.
   PubMed Web of Science ®Google Scholar
• Shaw LM, Korecka M, Clark CM, Lee VM, Trojanowski JQ. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discovery. 2007;6(4):295–303. doi:10.1038/nrd2176. PMID:17347655.
   PubMed Web of Science ®Google Scholar
• Blennow K, Vanmechelen E, Hampel H. CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol. 2001;24(1-3):87–97. doi:10.1385/MN:24:1-3:087. PMID:11831556.
   PubMed Web of Science ®Google Scholar
• Miles LA, Crespi GA, Doughty L, Parker MW. Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation. Scientific Reports. 2013;3:1302. doi:10.1038/srep01302. PMID:23416764.
   PubMed Web of Science ®Google Scholar
• Mehta AI, Brufsky AM, Sampson JH. Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier. Cancer Treat Rev. 2013;39(3):261–9. doi:10.1016/j.ctrv.2012.05.006. PMID:22727691.
   PubMed Web of Science ®Google Scholar
• Mueller BK, Yamashita T, Schaffar G, Mueller R. The role of repulsive guidance molecules in the embryonic and adult vertebrate central nervous system. Philos Trans R Soc Lond B Biol Sci. 2006;361(1473):1513–29. doi:10.1098/rstb.2006.1888. PMID:16939972.
   PubMed Web of Science ®Google Scholar
• Schwab JM, Monnier PP, Schluesener HJ, Conrad S, Beschorner R, Chen L, Meyermann R, Mueller BK. Central nervous system injury-induced repulsive guidance molecule expression in the adult human brain. Arch Neurol. 2005;62(10):1561–8. doi:10.1001/archneur.62.10.1561. PMID:16216939.
   PubMedGoogle Scholar
• Marques F, Sousa JC, Coppola G, Geschwind DH, Sousa N, Palha JA, Correia-Neves M. The choroid plexus response to a repeated peripheral inflammatory stimulus. BMC Neurosci. 2009;10:135. doi:10.1186/1471-2202-10-135. PMID:19922669.
   PubMed Web of Science ®Google Scholar
• McCoy MK, Tansey MG. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation. 2008;5:45. doi:10.1186/1742-2094-5-45. PMID:18925972.
   PubMed Web of Science ®Google Scholar
• Leal MC, Casabona JC, Puntel M, Pitossi FJ. Interleukin-1beta and tumor necrosis factor-alpha: reliable targets for protective therapies in Parkinson's Disease? Front Cell Neurosci. 2013;7:53.
   PubMed Web of Science ®Google Scholar
• Leung L, Cahill CM. TNF-alpha and neuropathic pain–a review. J Neuroinflammation. 2010;7:27. doi:10.1186/1742-2094-7-27. PMID:20398373.
   PubMed Web of Science ®Google Scholar
• Sade H, Baumgartner C, Hugenmatter A, Moessner E, Freskgard PO, Niewoehner J. A human blood-brain barrier transcytosis assay reveals antibody transcytosis influenced by pH-dependent receptor binding. PloS One. 2014;9(4):e96340. doi:10.1371/journal.pone.0096340. PMID:24788759.
   PubMed Web of Science ®Google Scholar
• Yi X, Manickam DS, Brynskikh A, Kabanov AV. Agile delivery of protein therapeutics to CNS. J Controll Rel. 2014;190:637–63. doi:10.1016/j.jconrel.2014.06.017.
   PubMed Web of Science ®Google Scholar
• Niewoehner J, Bohrmann B, Collin L, Urich E, Sade H, Maier P, Rueger P, Stracke JO, Lau W, Tissot AC, et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron. 2014;81(1):49–60. doi:10.1016/j.neuron.2013.10.061. PMID:24411731.
   PubMed Web of Science ®Google Scholar
• Goulatis LI, Shusta EV. Protein engineering approaches for regulating blood-brain barrier transcytosis. Curr Opin Struct Biol. 2016;45:109–15. doi:10.1016/j.sbi.2016.12.005. PMID:28040636.
   PubMed Web of Science ®Google Scholar
• Bell RD, Ehlers MD. Breaching the blood-brain barrier for drug delivery. Neuron. 2014;81(1):1–3. doi:10.1016/j.neuron.2013.12.023. PMID:24411725.
   PubMed Web of Science ®Google Scholar
• Moos T. Immunohistochemical localization of intraneuronal transferrin receptor immunoreactivity in the adult mouse central nervous system. J Comp Neurol. 1996;375(4):675–92. doi:10.1002/(SICI)1096-9861(19961125)375:4%3c675::AID-CNE8%3e3.0.CO;2-Z. PMID:8930792.
   PubMed Web of Science ®Google Scholar
• Roskams AJ, Connor JR. Transferrin receptor expression in myelin deficient (md) rats. J Neurosci Res. 1992;31(3):421–7. doi:10.1002/jnr.490310304. PMID:1640494.
   PubMed Web of Science ®Google Scholar
• Roskams AJ, Connor JR. Iron, transferrin, and ferritin in the rat brain during development and aging. J Neurochem. 1994;63(2):709–16. doi:10.1046/j.1471-4159.1994.63020709.x. PMID:8035195.
   PubMed Web of Science ®Google Scholar
• Boado RJ, Zhou QH, Lu JZ, Hui EK, Pardridge WM. Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor. Mol Pharm. 2010;7(1):237–44. doi:10.1021/mp900235k. PMID:19921848.
   PubMed Web of Science ®Google Scholar
• Byrne H, Conroy PJ, Whisstock JC, O'Kennedy RJ. A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications. Trends Biotechnol. 2013;31(11):621–32. doi:10.1016/j.tibtech.2013.08.007. PMID:24094861.
   PubMed Web of Science ®Google Scholar
• DiGiammarino E, Ghayur T, Liu J. Design and generation of DVD-Ig molecules for dual-specific targeting. Methods Mol Biol. 2012;899:145–56. doi:10.1007/978-1-61779-921-1_9. PMID:22735951.
   PubMedGoogle Scholar
• Pardridge WM, Boado RJ. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Methods Enzymol. 2012;503:269–92. doi:10.1016/B978-0-12-396962-0.00011-2. PMID:22230573.
   PubMed Web of Science ®Google Scholar
• Fendly BM, Toy KJ, Creasey AA, Vitt CR, Larrick JW, Yamamoto R, Lin LS. Murine monoclonal antibodies defining neutralizing epitopes on tumor necrosis factor. Hybridoma. 1987;6(4):359–70. doi:10.1089/hyb.1987.6.359. PMID:2442093.
   PubMedGoogle Scholar
• Severyn CJ, Shinde U, Rotwein P. Molecular biology, genetics and biochemistry of the repulsive guidance molecule family. Biochem J. 2009;422(3):393–403. doi:10.1042/BJ20090978. PMID:19698085.
   PubMedGoogle Scholar